基于代谢组学分析的18-三体妊娠羊水差异代谢物

摘要:目的通过 非靶向代谢组学方法分析18-三体( trisomy 18,T18) 妊娠母体羊水样本,探索其差异代谢物。方法采用病 例-对照研究,以8例18-三体妊娠母体羊水样本为病例组,40例正常胎儿母体羊水样本为对照组,采用气相色谱飞行时间质 谱技术( GC-T0F/MS)检测两组羊水样本。采用主成分分析(PCA)和正交偏最小二乘法判别分析(OPIS-DA)模型分析代谢谱 差异,通过单维统计分析寻找差异代谢物。结果PCA 和OPLS-DA模型分析均显示病例组与对照组之间无明显分离趋势。 通过单维分析在两组间共发现5种差异代谢物,分别为甘油醛、葡萄糖酸、硫酸吲哚酚.磷酸盐和泛酸(P<0.05)。结论羊水 代谢组学证实18-三体妊娠存在多种代谢物水平的差异,为疾病的发生机制的探索提供了更多研究思路。     

温针灸阳陵泉穴治疗膝关节骨性关节炎临床疗效观察

目的:观察温针灸阳陵泉穴治疗膝关节骨性关节炎的临床疗效。方法:将2015年1月至2019年1月本院收治的膝关节骨性关节炎患者120例,根据随机数字表法分为对照组和观察组,每组60例。对照组给予等速肌力训练治疗,观察组在对照组的基础上加用温针灸阳陵泉穴治疗。观察两组患者膝关节屈曲度、伸直度,白细胞介素(interleukin,IL)-6及IL-18水平,VAS评分及膝关节症状和功能评分。结果:观察组治疗后屈曲度及伸直度均高于对照组,差异有统计学意义(P<0.05);观察组治疗后IL-6及IL-18水平均低于对照组,差异有统计学意义(P<0.05);观察组治疗后VAS评分低于对照组,差异有统计学意义(P<0.05);观察组治疗后症状和功能评分高于对照组,差异有统计学意义(P<0.05);观察组有效率95.0%,对照组有效率83.3%,观察组有效率高于对照组,差异有统计学意义(P<0.05)。结论:温针灸阳陵泉穴治疗膝关节骨性关节炎,可有效改善患者膝关节活动度,降低炎症因子,减轻疼痛,提高临床疗效。     

18F-FDG PET/CT代谢的可重复性研究进展

18F-脱氧葡萄糖(18F-FDG)PET／CT在恶性肿瘤的早期诊断、临床分期、疗效评价、监测复发及肿瘤放疗靶区定位中具有重要价值。为了使PET/CT能够更准确地进行恶性肿瘤的疗效评价，18F-FDG PET／CT代谢的可重复性研究显得尤为重要。本文就传统临床代谢参数值标准化摄取值（SUV）、代谢活性肿瘤体积（MATV）、总病灶糖酵解（TLG）、肿瘤与肝脏比率（TLR）、肿瘤与血液比率(SUR)及近年新兴的PET图像纹理分析等方面的可重复性研究进行概述。     

SLC12A5 interacts and enhances SOX18 activity to promote bladder urothelial carcinoma progression via upregulating MMP7

Solute carrier family 12 member 5 (SLC12A5) has an oncogenic role in bladder urothelial carcinoma. The present study aimed to characterize the molecular mechanisms of SLC12A5 in bladder urothelial carcinoma pathogenesis. Functional assays identified that in bladder urothelial carcinoma SLC12A5 interacts with and stabilizes SOX18, and then upregulates matrix metalloproteinase 7 (MMP7). In vivo and in vitro assays were performed to confirm the effect of SLC12A5’s interaction with SOX18 on MMP7‐mediated bladder urothelial carcinoma progression. SLC12A5 was upregulated in human bladder tumors, and correlated with the poor survival of patients with bladder urothelial carcinoma tumor invasion and metastasis, promoted by SLC12A5 overexpression. We demonstrated that SLC12A5 interacted with SOX18, and then upregulated MMP7, thus enhancing tumor progression. Importantly, SLC12A5 expression correlated positively with SOX18 and MMP7 expression in bladder urothelial carcinoma. Furthermore, SLC12A5 expression was suppressed by miR‐133a‐3p. Ectopic expression of SLC12A5 partly abolished miR‐133a‐3p‐mediated suppression of cell migration. SLC12A5‐SOX18 complex‐mediated upregulation on MMP7 was important in bladder urothelial carcinoma progression. The miR‐133a‐3p/SLC12A5/SOX18/MMP7 signaling axis was critical for progression, and provided an effective therapeutic approach against bladder urothelial carcinoma.     

Initial evaluation of PET/CT with 18F‐FSU‐880 targeting prostate‐specific membrane antigen in prostate cancer patients

This first‐in‐man study was carried out to evaluate the safety, whole‐body distribution, dose estimation, and lesion accumulation of ¹⁸F‐FSU‐880, a newly developed probe targeting prostate‐specific membrane antigen. Six prostate cancer patients with known metastatic lesions underwent serial whole‐body PET/computed tomography (CT) with ¹⁸F‐FSU‐880. Blood and urine were analyzed before and after PET/CT. Accumulation of ¹⁸F‐FSU‐880 in organs and metastatic lesions in serial PET images were evaluated by measuring the standardized uptake values. From the biodistribution data, the organ doses and whole‐body effective dose were calculated using OLINDA/EXM software was developed by Dr. Michael Stabin of Vanderbilt University, Nashville, Tennessee, USA. ¹⁸F‐FSU‐880 PET/CT could be carried out without significant adverse effects. High physiological uptake was observed in the salivary/lachrymal glands and kidneys. The effective dose was calculated to be 0.921 × 10^?2 mSv/MBq. Known metastatic lesions were clearly visualized with high image contrast that increased with time, except in 1 patient, whose bone metastases were well‐controlled and inactive. The PET/CT with ¹⁸F‐FSU‐880 could be carried out safely and could clearly visualize active metastatic lesions. The present results warrant further clinical studies with a larger number of cases to verify the clinical utility of ¹⁸F‐FSU‐880 PET/CT in the management of prostate cancer patients.     

Source imaging of seizure onset predicts surgical outcome in pediatric epilepsy

ObjectiveTo assess whether ictal electric source imaging (ESI) on low-density scalp EEG can approximate the seizure onset zone (SOZ) location and predict surgical outcome in children with refractory epilepsy undergoing surgery.MethodsWe examined 35 children with refractory epilepsy. We dichotomized surgical outcome into seizure- and non-seizure-free. We identified ictal onsets recorded with scalp and intracranial EEG and localized them using equivalent current dipoles and standardized low-resolution magnetic tomography (sLORETA). We estimated the localization accuracy of scalp EEG as distance of scalp dipoles from intracranial dipoles. We also calculated the distances of scalp dipoles from resection, as well as their resection percentage and compared between seizure-free and non-seizure-free patients. We built receiver operating characteristic curves to test whether resection percentage predicted outcome.ResultsResection distance was lower in seizure-free patients for both dipoles (p = 0.006) and sLORETA (p = 0.04). Resection percentage predicted outcome with a sensitivity of 57.1% (95% CI, 34–78.2%), a specificity of 85.7% (95% CI, 57.2–98.2%) and an accuracy of 68.6% (95% CI, 50.7–83.5%) (p = 0.01).ConclusionIctal ESI performed on low-density scalp EEG can delineate the SOZ and predict outcome.SignificanceSuch an application may increase the number of children who are referred for epilepsy surgery and improve their outcome.